AGP Executive Report
Last update: 8 hours agoCancer Immunotherapy Breakthrough (Taiwan): NTUH researchers report a new way to “recharge” exhausted T cells in cancer patients, using BET inhibitors to rejuvenate immune cells and improve outcomes in animal studies, published in Nature Immunology. Public Health Alerts (Taiwan): Taiwan’s CDC flags a Kaohsiung hospital dengue cluster tied to an imported case, and also reports the youngest-ever Japanese encephalitis case. Health Safety (Taiwan): The Health Ministry warns travelers about fake Ebola certificates. Wellness & Community (Taiwan): Taiwan’s “Go Healthy with Taiwan 2026” campaign opens doors to South Africans, inviting health and wellness innovators to compete for awards and Taiwan visits. Pharma Deal (Greater China & beyond): Everest Medicines signs an exclusive licensing agreement with Dimerix for DMX-200, targeting kidney disease and autoimmune conditions across Taiwan and key Asian markets. Medical Tech Manufacturing (Taiwan): THY Precision says it’s supplying ultra-precision injection molds for silicone hydrogel contact lens production. Market Watch (Health-adjacent): A new report pegs the global GLP-1 receptor agonist market at $95.3B by 2035, reflecting continued obesity and diabetes demand.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://ml.globenewswire.com/Resource/Download/7b830788-22b5-4951-ae13-795b8c21bc2d/north-america-glp-1-receptor-agonist-market-size-2025-to-2035-usd-billion-.png)
